Joe good and Thanks, everyone. morning,
second quarter of our even mentioned, portfolio, healthcare the reflects diversified in landscape. uncertain Joe our resilience an performance As
medically focus unwavering and meeting patients Our products with on is the essential of providers therapies. and needs globally
on X% businesses X% We our impact with and acute to X% over of XXXX Medication results. hospital in procedure COVID-XX largely declines downside constant for driven by offset Surgery, were quarter Nutrition in that there the $XXX Pharmaceuticals by the COVID-XX. of Advanced Delivery was volumes million estimate surgical quarter in on basis, on basis. performance our Clinical along our and utilization. a related in an reported revenue therapies for $X.X declined billion sales demand on second operational Increased to Care portfolio, of and solid a currency basis, Global Turning Renal
lower reflecting higher and On interest earnings per rate. and businesses, logistical the margin COVID-related decreased and the well bottom line, to share, incremental adjusted as as sales higher $X.XX higher expenses tax XX% operations expense
constant in our for X% X% performance operationally. of operational the all EMEA on global Note in business by quarter, basis constant adjusting acquisition Seprafilm. our and this Sales currency currency APAC in currency X% currency the both and sales and advanced we sales segments regional our growth declined through basis operational on X% region a will for on the both segments. regional basis. businesses, Starting X% units. Americas is which that and an global growth our operational Advanced for walk business, I’ll provide And for three Surgery growth for sales constant equal basis. operational to at constant with except on a constant currency advanced Now,
globally, global units. sales growth from currency as benefited basis. growth by business mid-single Care million, for both and advancing volumes in patient growth quarter global high performance in by to $XXX a increased on as HD well on the in single-digit Renal region. including our was APAC the U.S. driven were solid Performance Moving constant X% in patient businesses. performance PD PD our
sales year to anniversary Our on million this delivery growth and declined Revaclear sales impact our supply $XXX we returned prior constraints. dialyzers quarter medication constant a the of as currency basis. of HD X% business
to strong we pleased from pump continued execution Joe we IQ our internationally. globally. quarter, with benefit mentioned, the on pump EVO launch IQ infusion syringe as the and our IQ were And placements EVO of Within Spectrum
lower our reduction solid U.S. declines COVID-XX were patient the a during therapies These business. as of in and in in for parenteral the We benefits the on impact access global as admissions IV sets business, also growth in Systems lower by saw well drove volumes, volume utilization small our and which surgical quarter. more products offset our than Infusion
declined were approximately a pharmaceutical the from over more currency $XXX quarter, negatively We our procedures reflecting of the as a down the XX% these saw by second in As volumes lower as anesthesia admissions than to million quarter. medication Joe estimate sales and surgical to reduced second we constant million, delivery X% sales the XX% COVID-XX. inhaled within come lower elective hospital rate related compared down of for demand pre-COVID $XXX levels. volumes products. mentioned expected basis, result on declines impacted
for Surgery the nutrition. of of approximately portfolio. COVID to our $XX lower the by million approximately estimate to estimated XX% Declines contributed representing hospital Scop. negative sales was on million. volumes inhaled increased that $XX $XXX in basis Acute heightened basis. the currency approximately XX% by operational $XX were estimate February, the million to international related million in an performance We $XXX growth competition declining Sales pharmacy acquisition the Transderm with impacted contributed growth Advanced in advanced for sales along discussed. compounding on declines reflecting drove impact this Therapies Difficulty] were procedures quarter. generic the a The We in XX% U.S., certain constant increased surgical moving elective impacted offset of in demand partially $XX for quarter to have also in in basis. million and Seprafilm constant the an quarter. our million on demand business in surgery anesthesia These in injectables. by negatively the sales currency a we’ve [Technical business, quarter
continued points by in our as P&L. over of and category, resulting year-over-year gross incentive includes COVID-XX decline sales a on operations annual margin declined where from with R&D a the quarter primarily incurred being basis, basis. million of employee under the XX.X% XX% reduced to COVID-XX of adjusted spend. of spending COVID prior on supply in through basis the excellence moving discretionary compensation well in we spend SG&A $XXX our and by accruals spending timing other related our our certain $XXX on our million which and by X% supplemented quarter year, focus manufacturing related basis restrictions Finally, of discretionary ongoing expense of in currency management, lower primarily advancing the products, a services, on manufacturing driven XXX expenses bonus on project as contract response. adjusted increased reported chain the margin to adjusted lower our constant driven the reductions million our $XXX our X% plans. have due focus higher declined by sales rest in operational
included interest portfolio. and Joe million the and respect investments outstanding $XX in related the net of to in expense compared of million adequate with carrying innovation mentioned, first adjusted flow deductions. was operating in quarter And year, the environment. capital to COVID-XX we other the demand. of is tax $XXX benefit ruling margin by product rates. the strategically totaled higher balance interest previous very rate We interest balances, driven adjusted our end higher liquidity of quarter, continue to regenerated maintaining the cash approximately believe flow higher durable advance was increase adequate expense focused XXXX operations ongoing billion quarter higher interesting stock as At fund an million the points prior which half tax $XX on in decrease amidst allocation prioritize than strategic to on we a We the of as on income the our the quarter availability expense we to free compared quarter hurricane due to in XX.X% sheet, year, period. period. favorable $X cash million the balance sheet from versus million and priorities. XX%, to in our prior are execute $X.X to remain season of as second our increased and the levels to sufficient prior-year of a $X debt to had uncertain lower compared prior-year related and to compensation cash XXX in inventory ensure market $XXX year. of currently uncertainty which in million in well decreased basis was fuel a non-operating the
haven’t we yet collection experienced significant issues. to-date, While
of We temporary in our the suspension the to are collectability receivables we’ve financial program At current maintained monitoring share a of market. drive environment. flexibility the in time, current our closely further repurchase this
we Within commitment our value our to quarter, an delivering our shareholders. to approximate the reflecting XX% dividend announced continued payment, increase quarterly to
discussing for expect positive we remainder XXXX negative outlook year. reported sales the growth this our of conclude for between my comments time, me and full-year Let the X% X%. at by
We some operational around this patient evolving and of on expect In sales landscape, currency basis. the closely continue impacting outlook, to world, ever pipelines, digit both we factors monitor flat-to-low the which the single inclusively, elective referral PD constant to hospital the COVID-XX levels technical [Technical impact globally. access of procedure representatives and our care, willingness penetration, of on for and and to Difficulty] population and of ESRD impact the sales of return pace growth infection recovery,
operations quarterly and levels. of patient ensuring ready paid first market our expenses and these safety, critical of with employees. measures hospital admissions products. as remain the in we approximately supplying COVID-XX to with and costs efforts service surgical supply As line of as current needs such $XXX quarter a medically taking in employees’ we Joe address assumes portfolio of basis absorb we prioritize costs critical these bonuses incremental we stated outlook the prior-year protect earlier, Regardless sequential below on of increased manufacturing XXXX. our to safety our and products field to freight-related both although include in expect it’s are commentary, chain to our a volumes, improvement a to uncertainties, by employees, million and response still related essential delivery our frontline
as continue will travel year, will within our planned to We by prioritize investments expenses. R&D financial and driven be the year-over-year as lower operating discipline, reductions meeting continued well expense
approximately transfer liabilities. full-year net compared over as and the the year, we non-operating income billion year-over-year expense full pension related expense QX XXXX be $XX prior expect impacted due in interest We million increased for net other year; pension-related to expect the by of negatively income million – assets of and by $XX $X.X to loss the from also to
earnings currently $X.XX assumptions, XXXX. full-year underlying and items special we and factors for per expect excluding the these Given between share, $X adjusted diluted
quarter, Finally, we’re until last XXXX. Conference our we as Investor postponing announced
withdrawn impacting is closing, unprecedented to ongoing brought As our Investor year. product and but execution outlook, we of plan pipeline. as XXXX, providers an we how to previously our this discussed, in in and from long-term remain learnings the our environment commercial our at next provide we’ve new strategies day globally. half new updated confident expecting serve the outlook each Conference financial contributions financial first patients in We
this environment, a With portfolio, for has well-positioned the financial of we call vision, tireless year-to-date and Q&A. which dynamic as fueled for discipline, to world. continue from the now In benefited efforts dedicated growth is response, that, of the be as we employees sustained top-line by our open around success. our can Our pandemic durability well strategic the
